Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:COGT NASDAQ:LNTH NASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$4.92+2.2%$5.22$4.57▼$8.69$1.80B0.422.85 million shs1.99 million shsCOGTCogent Biosciences$40.01+1.4%$34.81$9.13▼$43.73$6.74B0.342.99 million shs3.72 million shsLNTHLantheus$103.41+0.6%$99.32$47.25▼$111.86$6.69B-0.06909,610 shs1.15 million shsPTCTPTC Therapeutics$89.20+4.4%$74.39$43.17▼$89.80$7.09B0.532.73 million shs1.41 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-2.23%-0.50%-10.42%-8.20%-30.71%COGTCogent Biosciences+1.94%+1.81%+27.14%+10.72%+417.93%LNTHLantheus-6.43%-6.17%+1.82%+31.69%+29.81%PTCTPTC Therapeutics+2.56%+4.74%+20.39%+22.79%+75.19%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$4.92+2.2%$5.22$4.57▼$8.69$1.80B0.422.85 million shs1.99 million shsCOGTCogent Biosciences$40.01+1.4%$34.81$9.13▼$43.73$6.74B0.342.99 million shs3.72 million shsLNTHLantheus$103.41+0.6%$99.32$47.25▼$111.86$6.69B-0.06909,610 shs1.15 million shsPTCTPTC Therapeutics$89.20+4.4%$74.39$43.17▼$89.80$7.09B0.532.73 million shs1.41 million shsThe 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos-2.23%-0.50%-10.42%-8.20%-30.71%COGTCogent Biosciences+1.94%+1.81%+27.14%+10.72%+417.93%LNTHLantheus-6.43%-6.17%+1.82%+31.69%+29.81%PTCTPTC Therapeutics+2.56%+4.74%+20.39%+22.79%+75.19%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 1.80Reduce$8.0062.77% UpsideCOGTCogent Biosciences 2.86Moderate Buy$43.739.29% UpsideLNTHLantheus 2.73Moderate Buy$101.86-1.50% DownsidePTCTPTC Therapeutics 2.71Moderate Buy$91.572.66% UpsideCurrent Analyst Ratings BreakdownLatest BHC, LNTH, PTCT, and COGT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/7/2026PTCTPTC Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$82.00 ➝ $85.006/29/2026LNTHLantheus Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$115.006/9/2026PTCTPTC Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Buy$75.00 ➝ $108.005/29/2026COGTCogent Biosciences WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$55.005/27/2026LNTHLantheus MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$100.00 ➝ $115.005/27/2026PTCTPTC Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$76.00 ➝ $85.005/26/2026LNTHLantheus Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)5/11/2026PTCTPTC Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)5/11/2026LNTHLantheus Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$98.00 ➝ $115.005/8/2026PTCTPTC Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$94.005/8/2026LNTHLantheus CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 7/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$10.27B0.18$7.45 per share0.66$1.02 per share4.82COGTCogent BiosciencesN/AN/AN/AN/A$3.84 per shareN/ALNTHLantheus$1.54B4.37$6.42 per share16.10$16.43 per share6.29PTCTPTC Therapeutics$1.73B4.28$9.17 per share9.73($2.56) per share-34.84Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos$157M-$3.24N/A1.35N/A-11.47%-2,922.77%5.63%7/29/2026 (Estimated)COGTCogent Biosciences-$328.94M-$2.17N/AN/AN/AN/A-104.27%-54.64%8/4/2026 (Estimated)LNTHLantheus$233.56M$4.1524.9219.22N/A18.05%29.32%15.00%8/5/2026 (Estimated)PTCTPTC Therapeutics$682.64M-$2.33N/A42.273.93-22.58%-362.45%-6.76%8/6/2026 (Estimated)Latest BHC, LNTH, PTCT, and COGT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2026Q2 2026COGTCogent Biosciences-$0.55N/AN/AN/A$0.00 millionN/A7/29/2026Q2 2026BHCBausch Health Cos$0.96N/AN/AN/A$2.56 billionN/A5/7/2026Q1 2026LNTHLantheus$1.25$1.46+$0.21$1.80$354.48 million$377.33 million5/7/2026Q1 2026PTCTPTC Therapeutics-$0.45-$0.03+$0.42-$0.03$217.42 million$272.55 million5/5/2026Q1 2026COGTCogent Biosciences-$0.53-$0.53N/A-$0.53N/AN/A4/29/2026Q1 2026BHCBausch Health Cos$0.81$0.78-$0.03-$3.76$2.37 billion$2.46 billionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/ACOGTCogent BiosciencesN/AN/AN/AN/AN/ALNTHLantheusN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos54.681.320.97COGTCogent Biosciences0.4115.1415.14LNTHLantheus0.472.832.64PTCTPTC TherapeuticsN/A2.442.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%COGTCogent BiosciencesN/ALNTHLantheus99.06%PTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipBHCBausch Health Cos20.67%COGTCogent Biosciences6.59%LNTHLantheus1.70%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,300374.02 million296.71 millionOptionableCOGTCogent Biosciences80170.87 million159.61 millionOptionableLNTHLantheus1,19365.11 million64.00 millionOptionablePTCTPTC Therapeutics1,41082.95 million78.39 millionOptionableBHC, LNTH, PTCT, and COGT HeadlinesRecent News About These CompaniesPTC Therapeutics (NASDAQ:PTCT) Hits New 12-Month High - Should You Buy?July 7 at 2:39 PM | marketbeat.comCPRX's Agamree Shows Potential Beyond DMD After Positive Phase I DataJuly 2, 2026 | zacks.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Recommendation of "Moderate Buy" from BrokeragesJuly 2, 2026 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Consensus Rating of "Moderate Buy" from AnalystsJuly 2, 2026 | marketbeat.comNeil Gregory Almstead Sells 8,130 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJuly 1, 2026 | insidertrades.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells $693,163.80 in StockJune 30, 2026 | marketbeat.comPictet Asset Management Holding SA Has $80.06 Million Stock Holdings in PTC Therapeutics, Inc. $PTCTJune 30, 2026 | marketbeat.comLouisiana State Employees Retirement System Takes Position in PTC Therapeutics, Inc. $PTCTJune 30, 2026 | marketbeat.comOP Asset Management Ltd Acquires Shares of 33,602 PTC Therapeutics, Inc. $PTCTJune 28, 2026 | marketbeat.comNeil Gregory Almstead Sells 20,960 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 28, 2026 | americanbankingnews.comNeil Gregory Almstead Sells 5,323 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 27, 2026 | insidertrades.comPTC Therapeutics (NASDAQ:PTCT) Insider Neil Gregory Almstead Sells 5,323 SharesJune 26, 2026 | marketbeat.comPTC Therapeutics (NASDAQ:PTCT) Insider Sells 20,960 Shares of StockJune 26, 2026 | marketbeat.comNeil Gregory Almstead Sells 23,749 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 26, 2026 | americanbankingnews.comInsider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells $1,921,294.10 in StockJune 25, 2026 | insidertrades.comMark Elliott Boulding Sells 10,462 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 23, 2026 | insidertrades.comPTC Therapeutics, Inc. $PTCT Shares Sold by BI Asset Management Fondsmaeglerselskab A SJune 23, 2026 | marketbeat.comMark Elliott Boulding Sells 10,462 Shares of PTC Therapeutics (NASDAQ:PTCT) StockJune 22, 2026 | marketbeat.comPTC Therapeutics, Inc. $PTCT Shares Sold by Rockefeller Capital Management L.P.June 22, 2026 | marketbeat.comPacer Advisors Inc. Has $17.90 Million Position in PTC Therapeutics, Inc. $PTCTJune 21, 2026 | marketbeat.comPTC Therapeutics (PTCT) Moves 7.2% Higher: Will This Strength Last?June 18, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBHC, LNTH, PTCT, and COGT Company DescriptionsBausch Health Cos NYSE:BHC$4.92 +0.11 (+2.18%) Closing price 03:59 PM EasternExtended Trading$4.84 -0.08 (-1.61%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Cogent Biosciences NASDAQ:COGT$40.01 +0.57 (+1.45%) Closing price 04:00 PM EasternExtended Trading$39.75 -0.26 (-0.65%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.Lantheus NASDAQ:LNTH$103.41 +0.59 (+0.57%) Closing price 04:00 PM EasternExtended Trading$103.26 -0.16 (-0.15%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.PTC Therapeutics NASDAQ:PTCT$89.20 +3.76 (+4.40%) Closing price 04:00 PM EasternExtended Trading$88.84 -0.36 (-0.40%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Apple and Broadcom Forge a Decade-Long Silicon Fortress SK Hynix’s Nasdaq Listing Could Reset the AI Memory Trade The AI Chip Sell-Off Looks Scary, But the Real Story May Be Liquidity Palantir's CEO Just Called Out OpenAI and Anthropic Silicon Starvation: Amazon Feasts on Legacy GPUs GE Vernova’s Power Surge Turns the Grid Into an AI Trade 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers Abivax: Wall Street Catches Up to the Data Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
